Durvalumab + Tremelimumab
Phase 1TerminatedDevelopment Stage
Recurrent Gynecological Cancer
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
Jun 1, 2018 → Jul 15, 2022
About Durvalumab + Tremelimumab
Durvalumab + Tremelimumab is a phase 1 stage product being developed by AstraZeneca for Recurrent Gynecological Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03277482. Target conditions include Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer.
Hype Score Breakdown
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05345678 | Pre-clinical | Completed |
| NCT07081633 | Phase 2 | Recruiting |
| NCT05883644 | Phase 3 | Active |
| NCT05701488 | Phase 1 | Recruiting |
| NCT05557838 | Phase 3 | Recruiting |
| NCT04430452 | Phase 2 | Recruiting |
| NCT05000710 | Phase 2 | Active |
| NCT04499053 | Phase 2 | Recruiting |
| NCT04395079 | Phase 2 | Active |
| NCT04238637 | Phase 2 | Active |
| NCT03638141 | Phase 2 | Completed |
| NCT03702179 | Phase 2 | Completed |
| NCT03704480 | Phase 2 | Active |
| NCT03601455 | Phase 2 | Active |
| NCT03618134 | Phase 1/2 | Terminated |
| NCT03703297 | Phase 3 | Active |
| NCT03624231 | Phase 2 | Completed |
| NCT03288532 | Phase 3 | Recruiting |
| NCT03283605 | Phase 1/2 | Active |
| NCT03277482 | Phase 1 | Terminated |
Competing Products
20 competing products in Recurrent Gynecological Cancer